Sign inJoin waitlistJoin the waitlist

Ramzi Abboud

Blood and Marrow Transplant & Cellular/Gene Therapy Specialist, Hematologic Oncologist, Medical Oncologist · Alvin J. Siteman Cancer Center

Credentials: · · · · · ·

History

Washington University School of Medicine
2020–Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2017–2020
Internal Medicine
Barnes-Jewish Hospital
2014–2017
University of Rochester School of Medicine and Dentistry
2010–2014
University of Pennsylvania, Philadelphia, PA
2006–2010

Research

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Blood · 2008 · 142 citations
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well…
Biology of Blood and Marrow Transplantation · 2016 · First of 14 authors · 134 citations
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
Journal of Clinical Oncology · 2024 · 100 citations

John DiPersio
11 papers
Camille Abboud
8 papers
MS
Michael Slade
8 papers · 6 as a fellow
Mark Schroeder
7 papers
PW
Peter Westervelt
6 papers
Antonio Jimenez
5 papers
BS
Brian Shaffer
5 papers
Bronwen Shaw
5 papers
DM
Dipenkumar Modi
5 papers
ED
Elisa De-Togni
5 papers · 5 as a resident
FK
Farhad Khimani
5 papers
Geoffrey Uy
5 papers

Clinical trials

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Principal investigator · Recruiting · Phase 1
Washington University School of Medicine
2024–2027
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Principal investigator · Completed · Phase 1
Washington University School of Medicine
2019–2024
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029